ArticleEye (London, England)2019
A prospective study of the incidence, associations and outcomes of ocular surface squamous neoplasia in the United Kingdom.
Article in Eye (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- TFOS lifestyle: Impact of societal challenges on the ocular surface.The ocular surface · 2023Pooled it
- Effective Management of Recurrent Conjunctival Intraepithelial Neoplasia Using Topical Mitomycin C 0.02.Cureus · 2026Article
- Optical coherence tomography angiography in evaluating the response of ocular surface squamous neoplasia to topical immunotherapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Article
- Novel automated non-invasive detection of ocular surface squamous neoplasia using artificial intelligence.World journal of methodology · 2024Review
- Clinicopathological profile, management and clinical outcomes in recurrent cases of ocular surface squamous neoplasia at a tertiary care centre.International ophthalmology · 2023Article
- Ocular Surface Squamous Neoplasia: A 12-Month Prospective Evaluation of Incidence in Waikato, New Zealand.Vision (Basel, Switzerland) · 2022Article
- Ocular surface squamous neoplasia in India: a study of 438 patients.International ophthalmology · 2022Article
- Article
- Update on the Management of Ocular Surface Squamous Neoplasia.Current ophthalmology reports · 2021Article
- Topical interferon alpha-2b for a giant ocular surface squamous neoplasia: 7 years of follow-up after complete remission.BMJ case reports · 2021Article
- Acute anterior uveitis after topical interferon for conjunctival intraepithelial neoplasia (CIN).GMS ophthalmology cases · 2021Article
- Management Issues in Conjunctival Tumours: Ocular Surface Squamous Neoplasia.Ophthalmology and therapy · 2020Article
- Article
- PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.Investigative ophthalmology & visual science · 2019Article
- Pigmented versus nonpigmented ocular surface squamous neoplasia: A comparative study of 424 tumors.Taiwan journal of ophthalmologyArticle
- Ocular and periocular tumors in 855 Asian Indian geriatric patients.Oman journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the incidence, associations and outcomes of ocular surface squamous neoplasia (OSSN) in the United Kingdom.
methodsProspective, observational study of every new case of OSSN reported via the British Ophthalmological Surveillance Unit reporting scheme over a 12-month period. Cases were followed up for 12 months.
resultsThe reported incidence of OSSN was 0.53 cases/million/year (conjunctival intraepithelial neoplasia: 0.43 cases/million/year; squamous cell carcinoma: 0.08 cases/million/year). Eighty-five per cent of affected patients were male, 97% were Caucasian, and the mean age at presentation was 67.9 (±12.8) years. Information on potential underlying risk factors was frequently unknown. The most commonly affected sites were the limbus and the nasal and temporal bulbar conjunctivae. Most patients presented with a visual acuity of 6/9 or better, without symptoms of pain or visual loss. Excision (with or without additional treatment) was the most common first-line treatment and interferon (with or without additional treatment) was the most common second-line treatment, although management varied widely. Complications of treatment were rare but occasionally severe. Recurrence within 12 months of follow-up occurred in at least 6% of patients.
conclusionAlthough subject to reporting bias, these data suggest that there has not been a significant change in the incidence of OSSN in the United Kingdom, or its demographic profile, since 1996. The broad range of management approaches identified in this study reflect a lack of consensus as to the optimal referral and treatment pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.